Aytu BioPharma (NASDAQ:AYTU – Get Free Report) issued its earnings results on Monday. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06, Zacks reports. Aytu BioPharma had a negative net margin of 24.76% and a negative return on equity of 56.54%.
Aytu BioPharma Stock Up 2.2%
Aytu BioPharma stock traded up $0.04 during midday trading on Monday, hitting $1.82. 40,238 shares of the company were exchanged, compared to its average volume of 46,495. The company has a market cap of $19.78 million, a PE ratio of -1.10 and a beta of 0.24. Aytu BioPharma has a fifty-two week low of $1.75 and a fifty-two week high of $3.06. The company’s fifty day moving average price is $2.01 and its 200-day moving average price is $2.28. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.13 and a quick ratio of 1.00.
Analyst Ratings Changes
Several equities analysts recently weighed in on AYTU shares. Citigroup reaffirmed a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday, September 22nd. Weiss Ratings downgraded Aytu BioPharma from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, October 6th. Finally, Zacks Research lowered Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Aytu BioPharma has a consensus rating of “Hold” and an average price target of $14.50.
Check Out Our Latest Research Report on Aytu BioPharma
About Aytu BioPharma
Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.
Read More
- Five stocks we like better than Aytu BioPharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
